![Melanie Lee](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Melanie Lee
Vorstandsvorsitzender bei
Lifearc Ventures
Profil
Melanie Georgina Lee is the founder.
Dr. Lee was the founder of NightstaRx Ltd. (2014), holding the title of Chief Executive Officer.
Dr. Lee is also the founder of Think10.
Current jobs include Chief Executive Officer at Lifearc Ventures, Non-Executive Director at BIAL-Portela & Cia SA since 2023, Director at Lee & Smith Properties Ltd., and Trustee at UK DRI Ltd. since 2017.
Former jobs include Chairman at Cancer Research Technology Ltd. (2004-2007), Deputy Chairman at Cancer Research UK (2003-2011), Independent Non-Executive Director at H.
Lundbeck A (2015), Independent Director at Sanofi (2017-2022), Independent Non-Executive Director at BTG Ltd. (2012-2014), Director-Research & Development at Celltech Group Ltd. (1998-2009), Director at Ipsen Bioinnovation Ltd. (2009-2013), Chief Scientific Officer at BTG Ltd. (2014-2018), Research Unit Head-Receptor Systems at GlaxoWellcome (1988-1998), Executive Vice President-Research & Development at UCB Pharma, Inc., Principal at GlaxoSmithKline Pharmaceuticals SA (Belgium), and President-New Medicines at UCB Celltech (1998-2009).
Education includes an undergraduate degree from York University and a doctorate from The National Institute For Medical Research.
Aktive Positionen von Melanie Lee
| Unternehmen | Position | Beginn |
|---|---|---|
UK DRI Ltd.
 UK DRI Ltd. BiotechnologyHealth Technology Operates as research institute to prevent, treat and care for people with all types of dementia | Direktor/Vorstandsmitglied | 20.12.2017 |
Lee & Smith Properties Ltd. | Direktor/Vorstandsmitglied | - |
BIAL-Portela & Cia SA
 BIAL-Portela & Cia SA Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceuticals | Direktor/Vorstandsmitglied | 23.05.2023 |
Lifearc Ventures
 Lifearc Ventures Investment ManagersFinance Lifearc Ventrues invests in companies located in the United Kingdom. The firm targets companies operating in the fields of therapeutics, healthtech and medtech sectors. It provides financing for seed and early stage capital requirements. makes follow-on investments. It acts as a co-investor and also makes follow-on investments. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Melanie Lee
| Unternehmen | Position | Ende |
|---|---|---|
| SANOFI | Direktor/Vorstandsmitglied | 03.05.2022 |
| BTG | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2018 |
| H. LUNDBECK A/S | Direktor/Vorstandsmitglied | 25.03.2015 |
| BTG | Direktor/Vorstandsmitglied | 25.09.2014 |
Ipsen Bioinnovation Ltd.
 Ipsen Bioinnovation Ltd. BiotechnologyHealth Technology Engages in research and experimental development on biotechnology | Direktor/Vorstandsmitglied | 01.01.2013 |
Ausbildung von Melanie Lee
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
80
Beziehungen ersten Grades
19
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 19 |
|---|---|
H. Lundbeck A/S
 H. Lundbeck A/S Pharmaceuticals: MajorHealth Technology Engages in the research, development, production and sale of pharmaceuticals for the treatment of brain diseases | Health Technology |
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
BTG Ltd.
 BTG Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and supplies drugs used in the treatment of neurological disorders | Health Technology |
BIAL-Portela & Cia SA
BIAL-Portela & Cia SA Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceuticals | Health Technology |
GlaxoWellcome /Pharmocology Unit/
 GlaxoWellcome /Pharmocology Unit/ Miscellaneous Commercial ServicesCommercial Services Provides research and development services to the pharmaceutical industry | Commercial Services |
York University
 York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cancer Research Technology Ltd.
 Cancer Research Technology Ltd. Medical SpecialtiesHealth Technology Develops cancer therapeutics, vaccines, and diagnostics | Health Technology |
UCB Pharma, Inc.
 UCB Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research, development & commercialisation of pharmeceutical and biotechnology products | Commercial Services |
Cancer Research UK
 Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Provides cancer research services | Commercial Services |
The National Institute For Medical Research
 The National Institute For Medical Research Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GlaxoSmithKline Pharmaceuticals SA (Belgium)
 GlaxoSmithKline Pharmaceuticals SA (Belgium) Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals and vaccines | Health Technology |
Celltech Group Ltd.
 Celltech Group Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Finance |
UCB Celltech
 UCB Celltech BiotechnologyHealth Technology Develops novel therapeutic products for human | Health Technology |
Think10 | |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services development of therapies for retinal dystrophies | Health Services |
Ipsen Bioinnovation Ltd.
Ipsen Bioinnovation Ltd. BiotechnologyHealth Technology Engages in research and experimental development on biotechnology | Health Technology |
UK DRI Ltd.
UK DRI Ltd. BiotechnologyHealth Technology Operates as research institute to prevent, treat and care for people with all types of dementia | Health Technology |
Lee & Smith Properties Ltd. | |
Lifearc Ventures
Lifearc Ventures Investment ManagersFinance Lifearc Ventrues invests in companies located in the United Kingdom. The firm targets companies operating in the fields of therapeutics, healthtech and medtech sectors. It provides financing for seed and early stage capital requirements. makes follow-on investments. It acts as a co-investor and also makes follow-on investments. | Finance |
